Shane Jenson
Family · Helena, MTNPI 1346482916
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,096 of the $1,753 with a category attached, or 62.5%. Boston Scientific accounts for 77.5% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $1,387, more than ten times the $14 reported in 2021. Among family clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $125.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Pfizer$82
- Vertex$80
- Averitas Pharma Inc.$66
- Medtronic$41
- Exact Sciences$34
- plus $93 from 4 others
What the payments were for
- Travel & lodging$1,09663%
- Food & beverage$65737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $1,358 |
| Pfizer | 1 | $82 |
| Vertex | 1 | $80 |
| Averitas Pharma Inc. | 1 | $66 |
| Medtronic | 1 | $41 |
| Exact Sciences | 1 | $34 |
| Merck | 2 | $30 |
| Avanos Medical | 1 | $29 |
| Novo Nordisk | 1 | $20 |
| Indivior Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,284
How this compares
$1,753 in reported general payments places this provider in the 90th percentile of 481 family providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 15 | $13,480 |
| Buprenorphine | 19 | $7,270 |
| Metaxalone | 13 | $6,579 |
| Morphine Sulfate ErMorphine Sulfate | 19 | $536 |
| Gabapentin | 23 | $436 |
| Pregabalin | 20 | $368 |
| Celecoxib | 15 | $90 |
| Tramadol Hcl | 13 | $26 |
| Meloxicam | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Other family in Helena
- Kara AddisonHelena$50K
- Jessica HavensHelena$11K
- Tara WellsHelena$10K
- Mary MiddaghHelena$6K
- Megan GittingsHelena$4K
- Jeannie FahlquistHelena$3K
- Christopher VanhorssenHelena$3K
- Willow SheehanHelena$3K
- Leigha ShilhanekHelena$3K
- Lindsay McCarthyHelena$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.